|
Registrierung und Veröffentlichung aller klinischen Studien in Deutschland
|
01 February 2023 |
|
Getting all clinical trials registered and reported in Germany
|
25 January 2023 |
|
Multi-Modal Cancer Screening Tests: Hype or Hope
|
25 January 2023 |
|
Using evidence to inform practice: Lessons from NICE
|
25 January 2023 |
|
De-escalation in Cancer Care
|
25 January 2023 |
|
Why retractions are on the rise.
|
25 January 2023 |
|
Detecting problematic RCTs
|
25 January 2023 |
|
The wind that shook the Sugary Willows
|
25 January 2023 |
|
Which medicines should be used in cancer care?
|
25 January 2023 |
|
Pathological Consensus
|
24 January 2023 |
|
The waste in futile oncology drug development
|
24 January 2023 |
|
Predictive validity in drug discovery: what it is, why it matters and how to improve it?
|
24 January 2023 |
|
Transformative Innovation Policy
|
24 January 2023 |
|
Busting 2 zombie trials in a post-Covid world
|
24 January 2023 |
|
Event 5 – HTA in Low-to-Middle-Income Countries
|
24 January 2023 |
|
Event 4 – Translation into practice
|
24 January 2023 |
|
Event 3 - Evaluation Process and Methods
|
24 January 2023 |
|
Event 2 - Regulation and HTA
|
24 January 2023 |
|
Event 1 - Evidence Generation: Quality of data for decision-making
|
24 January 2023 |
|
Alternative medicine: research and integrity
|
24 January 2023 |
|
Brainstorm: How can we fix the global clinical trial registry system?
|
24 January 2023 |
|
Evaluation Process and Methods
|
08 September 2022 |
|
IP and access to health technologies
|
08 September 2022 |
|
Predictive validity in drug discovery
|
08 September 2022 |
|
Fixing Trial Registries
|
08 September 2022 |
|
HTA in Low-to-Middle-Income Countries
|
08 September 2022 |
|
Translation into Practice
|
08 September 2022 |
